HomeCompareTSIFX vs ABBV

TSIFX vs ABBV: Dividend Comparison 2026

TSIFX yields 180.08% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TSIFX wins by $65.80M in total portfolio value
10 years
TSIFX
TSIFX
● Live price
180.08%
Share price
$2.73
Annual div
$4.92
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$65.90M
Annual income
$31,496,496.75
Full TSIFX calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — TSIFX vs ABBV

📍 TSIFX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTSIFXABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TSIFX + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TSIFX pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TSIFX
Annual income on $10K today (after 15% tax)
$15,306.66/yr
After 10yr DRIP, annual income (after tax)
$26,772,022.24/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, TSIFX beats the other by $26,750,966.23/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TSIFX + ABBV for your $10,000?

TSIFX: 50%ABBV: 50%
100% ABBV50/50100% TSIFX
Portfolio after 10yr
$33.00M
Annual income
$15,760,634.25/yr
Blended yield
47.76%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

TSIFX
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TSIFX buys
0
ABBV buys
0
No recent congressional trades found for TSIFX or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTSIFXABBV
Forward yield180.08%3.06%
Annual dividend / share$4.92$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$65.90M$102.3K
Annual income after 10y$31,496,496.75$24,771.77
Total dividends collected$61.73M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: TSIFX vs ABBV ($10,000, DRIP)

YearTSIFX PortfolioTSIFX Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$28,708$18,007.84$11,550$430.00+$17.2KTSIFX
2$79,032$48,314.59$13,472$627.96+$65.6KTSIFX
3$208,872$124,307.38$15,906$926.08+$193.0KTSIFX
4$530,529$307,036.24$19,071$1,382.55+$511.5KTSIFX
5$1,296,511$728,845.52$23,302$2,095.81+$1.27MTSIFX
6$3,051,902$1,664,635.08$29,150$3,237.93+$3.02MTSIFX
7$6,927,630$3,662,094.53$37,536$5,121.41+$6.89MTSIFX
8$15,181,469$7,768,905.40$50,079$8,338.38+$15.13MTSIFX
9$32,155,455$15,911,282.40$69,753$14,065.80+$32.09MTSIFX
10$65,902,833$31,496,496.75$102,337$24,771.77+$65.80MTSIFX

TSIFX vs ABBV: Complete Analysis 2026

TSIFXStock

Tortoise Tax-Advantaged Social Infrastructure Fund, Inc. operates as a closed-end investment fund. It provides investment advisory services to the fund and advisers. The company is headquartered in Overland Park, KS.

Full TSIFX Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this TSIFX vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TSIFX vs SCHDTSIFX vs JEPITSIFX vs OTSIFX vs KOTSIFX vs MAINTSIFX vs JNJTSIFX vs MRKTSIFX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.